Rivaroxaban  ||| S:0 E:12 ||| NNP
for  ||| S:12 E:16 ||| IN
the  ||| S:16 E:20 ||| DT
prevention  ||| S:20 E:31 ||| NN
of  ||| S:31 E:34 ||| IN
venous  ||| S:34 E:41 ||| JJ
thromboembolism ||| S:41 E:56 ||| NN
:  ||| S:56 E:58 ||| :
a  ||| S:58 E:60 ||| DT
single  ||| S:60 E:67 ||| JJ
technology  ||| S:67 E:78 ||| NN
appraisal  ||| S:78 E:88 ||| VBD
This  ||| S:88 E:93 ||| DT
paper  ||| S:93 E:99 ||| NN
presents  ||| S:99 E:108 ||| VBZ
a  ||| S:108 E:110 ||| DT
summary  ||| S:110 E:118 ||| NN
of  ||| S:118 E:121 ||| IN
the  ||| S:121 E:125 ||| DT
evidence  ||| S:125 E:134 ||| NN
review  ||| S:134 E:141 ||| NN
group  ||| S:141 E:147 ||| NN
( ||| S:147 E:148 ||| -LRB-
ERG ||| S:148 E:151 ||| NNP
)  ||| S:151 E:153 ||| -RRB-
report  ||| S:153 E:160 ||| NN
into  ||| S:160 E:165 ||| IN
the  ||| S:165 E:169 ||| DT
clinical  ||| S:169 E:178 ||| JJ
effectiveness  ||| S:178 E:192 ||| NN
and  ||| S:192 E:196 ||| CC
cost-effectiveness  ||| S:196 E:215 ||| JJ
of  ||| S:215 E:218 ||| IN
rivaroxaban  ||| S:218 E:230 ||| NN
for  ||| S:230 E:234 ||| IN
the  ||| S:234 E:238 ||| DT
prevention  ||| S:238 E:249 ||| NN
of  ||| S:249 E:252 ||| IN
venous  ||| S:252 E:259 ||| JJ
thromboembolism  ||| S:259 E:275 ||| NNS
( ||| S:275 E:276 ||| -LRB-
VTE ||| S:276 E:279 ||| NNP
)  ||| S:279 E:281 ||| -RRB-
in  ||| S:281 E:284 ||| IN
adult  ||| S:284 E:290 ||| NN
patients  ||| S:290 E:299 ||| NNS
undergoing  ||| S:299 E:310 ||| VBG
elective  ||| S:310 E:319 ||| JJ
hip  ||| S:319 E:323 ||| NN
or  ||| S:323 E:326 ||| CC
knee  ||| S:326 E:331 ||| JJ
replacement  ||| S:331 E:343 ||| NN
surgery  ||| S:343 E:351 ||| NN
based  ||| S:351 E:357 ||| VBN
upon  ||| S:357 E:362 ||| IN
a  ||| S:362 E:364 ||| DT
review  ||| S:364 E:371 ||| NN
of  ||| S:371 E:374 ||| IN
the  ||| S:374 E:378 ||| DT
manufacturer ||| S:378 E:390 ||| NN
's  ||| S:390 E:393 ||| POS
submission  ||| S:393 E:404 ||| NN
to  ||| S:404 E:407 ||| TO
the  ||| S:407 E:411 ||| DT
National  ||| S:411 E:420 ||| NNP
Institute  ||| S:420 E:430 ||| NNP
for  ||| S:430 E:434 ||| IN
Health  ||| S:434 E:441 ||| NNP
and  ||| S:441 E:445 ||| CC
Clinical  ||| S:445 E:454 ||| NNP
Excellence  ||| S:454 E:465 ||| NNP
( ||| S:465 E:466 ||| -LRB-
NICE ||| S:466 E:470 ||| NNP
)  ||| S:470 E:472 ||| -RRB-
as  ||| S:472 E:475 ||| IN
part  ||| S:475 E:480 ||| NN
of  ||| S:480 E:483 ||| IN
the  ||| S:483 E:487 ||| DT
single  ||| S:487 E:494 ||| JJ
technology  ||| S:494 E:505 ||| NN
appraisal  ||| S:505 E:515 ||| NN
( ||| S:515 E:516 ||| -LRB-
STA ||| S:516 E:519 ||| NNP
)  ||| S:519 E:521 ||| -RRB-
process ||| S:521 E:528 ||| NN
.  ||| S:528 E:530 ||| .
The  ||| S:530 E:534 ||| DT
submission ||| S:534 E:544 ||| NN
's  ||| S:544 E:547 ||| POS
evidence  ||| S:547 E:556 ||| NN
came  ||| S:556 E:561 ||| VBD
from  ||| S:561 E:566 ||| IN
four  ||| S:566 E:571 ||| CD
randomised  ||| S:571 E:582 ||| NNS
controlled  ||| S:582 E:593 ||| VBN
trials  ||| S:593 E:600 ||| NNS
( ||| S:600 E:601 ||| -LRB-
RCTs ||| S:601 E:605 ||| NNP
)  ||| S:605 E:607 ||| -RRB-
comparing  ||| S:607 E:617 ||| VBG
rivaroxaban  ||| S:617 E:629 ||| NN
with  ||| S:629 E:634 ||| IN
enoxaparin  ||| S:634 E:645 ||| NNS
[ ||| S:645 E:646 ||| -LRB-
RECORD  ||| S:646 E:653 ||| NNP
( ||| S:653 E:654 ||| -LRB-
Regulation  ||| S:654 E:665 ||| NNP
of  ||| S:665 E:668 ||| IN
Coagulation  ||| S:668 E:680 ||| NNP
in  ||| S:680 E:683 ||| IN
Orthopedic  ||| S:683 E:694 ||| NNP
surgery  ||| S:694 E:702 ||| NN
to  ||| S:702 E:705 ||| TO
pRevent  ||| S:705 E:713 ||| JJ
Deep  ||| S:713 E:718 ||| JJ
venous  ||| S:718 E:725 ||| JJ
thrombosis  ||| S:725 E:736 ||| NN
and  ||| S:736 E:740 ||| CC
pulmonary  ||| S:740 E:750 ||| JJ
embolism ||| S:750 E:758 ||| NN
)  ||| S:758 E:760 ||| -RRB-
1-4 ||| S:760 E:763 ||| CD
]  ||| S:763 E:765 ||| -RRB-
and  ||| S:765 E:769 ||| CC
three  ||| S:769 E:775 ||| CD
comparing  ||| S:775 E:785 ||| JJ
dabigatran  ||| S:785 E:796 ||| NN
with  ||| S:796 E:801 ||| IN
enoxaparin  ||| S:801 E:812 ||| NNS
[ ||| S:812 E:813 ||| -LRB-
RE-NOVATE  ||| S:813 E:823 ||| NNP
( ||| S:823 E:824 ||| -LRB-
the  ||| S:824 E:828 ||| DT
prevention  ||| S:828 E:839 ||| NN
of  ||| S:839 E:842 ||| IN
venous  ||| S:842 E:849 ||| JJ
thromboembolism  ||| S:849 E:865 ||| NN
after  ||| S:865 E:871 ||| IN
total  ||| S:871 E:877 ||| JJ
hip  ||| S:877 E:881 ||| JJ
replacement  ||| S:881 E:893 ||| NN
trial ||| S:893 E:898 ||| NN
) ||| S:898 E:899 ||| -RRB-
,  ||| S:899 E:901 ||| ,
RE-MODEL  ||| S:901 E:910 ||| NNP
( ||| S:910 E:911 ||| -LRB-
the  ||| S:911 E:915 ||| DT
prevention  ||| S:915 E:926 ||| NN
of  ||| S:926 E:929 ||| IN
venous  ||| S:929 E:936 ||| JJ
thromboembolism  ||| S:936 E:952 ||| NN
after  ||| S:952 E:958 ||| IN
total  ||| S:958 E:964 ||| JJ
knee  ||| S:964 E:969 ||| NN
replacement  ||| S:969 E:981 ||| NN
trial ||| S:981 E:986 ||| NN
)  ||| S:986 E:988 ||| -RRB-
and  ||| S:988 E:992 ||| CC
RE-MOBILIZE  ||| S:992 E:1004 ||| NNP
( ||| S:1004 E:1005 ||| -LRB-
the  ||| S:1005 E:1009 ||| DT
prevention  ||| S:1009 E:1020 ||| NN
of  ||| S:1020 E:1023 ||| IN
venous  ||| S:1023 E:1030 ||| JJ
thromboembolism  ||| S:1030 E:1046 ||| NN
after  ||| S:1046 E:1052 ||| IN
total  ||| S:1052 E:1058 ||| JJ
knee  ||| S:1058 E:1063 ||| NN
arthroplasty  ||| S:1063 E:1076 ||| NN
trial ||| S:1076 E:1081 ||| NN
) ||| S:1081 E:1082 ||| -RRB-
] ||| S:1082 E:1083 ||| -RRB-
.  ||| S:1083 E:1085 ||| .
The  ||| S:1085 E:1089 ||| DT
evidence  ||| S:1089 E:1098 ||| NN
from  ||| S:1098 E:1103 ||| IN
the  ||| S:1103 E:1107 ||| DT
four  ||| S:1107 E:1112 ||| CD
RECORD  ||| S:1112 E:1119 ||| NN
trials  ||| S:1119 E:1126 ||| NNS
indicates  ||| S:1126 E:1136 ||| VBZ
that  ||| S:1136 E:1141 ||| DT
rivaroxaban  ||| S:1141 E:1153 ||| NN
had  ||| S:1153 E:1157 ||| VBD
superior  ||| S:1157 E:1166 ||| JJ
efficacy  ||| S:1166 E:1175 ||| NN
over  ||| S:1175 E:1180 ||| IN
enoxaparin  ||| S:1180 E:1191 ||| NN
after  ||| S:1191 E:1197 ||| IN
total  ||| S:1197 E:1203 ||| JJ
hip  ||| S:1203 E:1207 ||| JJ
replacement  ||| S:1207 E:1219 ||| NN
( ||| S:1219 E:1220 ||| -LRB-
THR ||| S:1220 E:1223 ||| NNP
)  ||| S:1223 E:1225 ||| -RRB-
and  ||| S:1225 E:1229 ||| CC
total  ||| S:1229 E:1235 ||| JJ
knee  ||| S:1235 E:1240 ||| NN
replacement  ||| S:1240 E:1252 ||| NN
( ||| S:1252 E:1253 ||| -LRB-
TKR ||| S:1253 E:1256 ||| NNP
) ||| S:1256 E:1257 ||| -RRB-
.  ||| S:1257 E:1259 ||| .
For  ||| S:1259 E:1263 ||| IN
the  ||| S:1263 E:1267 ||| DT
composite  ||| S:1267 E:1277 ||| JJ
primary  ||| S:1277 E:1285 ||| JJ
outcome  ||| S:1285 E:1293 ||| NN
of  ||| S:1293 E:1296 ||| IN
any  ||| S:1296 E:1300 ||| DT
deep  ||| S:1300 E:1305 ||| JJ
vein  ||| S:1305 E:1310 ||| NN
thrombosis  ||| S:1310 E:1321 ||| NNS
( ||| S:1321 E:1322 ||| -LRB-
DVT ||| S:1322 E:1325 ||| NNP
) ||| S:1325 E:1326 ||| -RRB-
,  ||| S:1326 E:1328 ||| ,
non-fatal  ||| S:1328 E:1338 ||| FW
pulmonary  ||| S:1338 E:1348 ||| FW
embolism  ||| S:1348 E:1357 ||| FW
( ||| S:1357 E:1358 ||| -LRB-
PE ||| S:1358 E:1360 ||| NNP
)  ||| S:1360 E:1362 ||| -RRB-
and  ||| S:1362 E:1366 ||| CC
death  ||| S:1366 E:1372 ||| NN
from  ||| S:1372 E:1377 ||| IN
all  ||| S:1377 E:1381 ||| DT
causes  ||| S:1381 E:1388 ||| VBZ
the  ||| S:1388 E:1392 ||| DT
relative  ||| S:1392 E:1401 ||| JJ
risk  ||| S:1401 E:1406 ||| NN
reductions  ||| S:1406 E:1417 ||| NNS
were  ||| S:1417 E:1422 ||| VBD
70-79 ||| S:1422 E:1427 ||| CD
%  ||| S:1427 E:1429 ||| NN
in  ||| S:1429 E:1432 ||| IN
THR  ||| S:1432 E:1436 ||| NNP
and  ||| S:1436 E:1440 ||| CC
31-49 ||| S:1440 E:1445 ||| CD
%  ||| S:1445 E:1447 ||| NN
in  ||| S:1447 E:1450 ||| IN
TKR ||| S:1450 E:1453 ||| NNP
.  ||| S:1453 E:1455 ||| .
Rivaroxaban  ||| S:1455 E:1467 ||| NNP
also  ||| S:1467 E:1472 ||| RB
had  ||| S:1472 E:1476 ||| VBD
superior  ||| S:1476 E:1485 ||| JJ
efficacy  ||| S:1485 E:1494 ||| NN
over  ||| S:1494 E:1499 ||| IN
enoxaparin  ||| S:1499 E:1510 ||| NN
for  ||| S:1510 E:1514 ||| IN
the  ||| S:1514 E:1518 ||| DT
secondary  ||| S:1518 E:1528 ||| JJ
outcome  ||| S:1528 E:1536 ||| NN
major  ||| S:1536 E:1542 ||| JJ
VTE ||| S:1542 E:1545 ||| NNP
.  ||| S:1545 E:1547 ||| .
Rivaroxaban  ||| S:1547 E:1559 ||| NNP
was  ||| S:1559 E:1563 ||| VBD
not  ||| S:1563 E:1567 ||| RB
inferior  ||| S:1567 E:1576 ||| JJ
to  ||| S:1576 E:1579 ||| TO
enoxaparin  ||| S:1579 E:1590 ||| VB
on  ||| S:1590 E:1593 ||| IN
the  ||| S:1593 E:1597 ||| DT
safety  ||| S:1597 E:1604 ||| NN
outcome  ||| S:1604 E:1612 ||| NN
of  ||| S:1612 E:1615 ||| IN
major  ||| S:1615 E:1621 ||| JJ
bleeding ||| S:1621 E:1629 ||| NN
.  ||| S:1629 E:1631 ||| .
After  ||| S:1631 E:1637 ||| IN
the  ||| S:1637 E:1641 ||| DT
correction  ||| S:1641 E:1652 ||| NN
of  ||| S:1652 E:1655 ||| IN
some  ||| S:1655 E:1660 ||| DT
errors  ||| S:1660 E:1667 ||| NNS
found  ||| S:1667 E:1673 ||| VBD
by  ||| S:1673 E:1676 ||| IN
the  ||| S:1676 E:1680 ||| DT
ERG ||| S:1680 E:1683 ||| NNP
,  ||| S:1683 E:1685 ||| ,
the  ||| S:1685 E:1689 ||| DT
manufacturer ||| S:1689 E:1701 ||| NN
's  ||| S:1701 E:1704 ||| POS
economic  ||| S:1704 E:1713 ||| JJ
model  ||| S:1713 E:1719 ||| NN
represented  ||| S:1719 E:1731 ||| VBD
a  ||| S:1731 E:1733 ||| DT
reasonable  ||| S:1733 E:1744 ||| JJ
model  ||| S:1744 E:1750 ||| NN
of  ||| S:1750 E:1753 ||| IN
patients  ||| S:1753 E:1762 ||| NNS
receiving  ||| S:1762 E:1772 ||| VBG
prophylaxis  ||| S:1772 E:1784 ||| NN
for  ||| S:1784 E:1788 ||| IN
THR  ||| S:1788 E:1792 ||| NNP
or  ||| S:1792 E:1795 ||| CC
TKR ||| S:1795 E:1798 ||| NNP
.  ||| S:1798 E:1800 ||| .
In  ||| S:1800 E:1803 ||| IN
the  ||| S:1803 E:1807 ||| DT
base-case  ||| S:1807 E:1817 ||| JJ
analyses  ||| S:1817 E:1826 ||| NNS
rivaroxaban  ||| S:1826 E:1838 ||| VBP
dominated  ||| S:1838 E:1848 ||| VBN
both  ||| S:1848 E:1853 ||| DT
enoxaparin  ||| S:1853 E:1864 ||| NN
and  ||| S:1864 E:1868 ||| CC
dabigatran ||| S:1868 E:1878 ||| NN
.  ||| S:1878 E:1880 ||| .
The  ||| S:1880 E:1884 ||| DT
incremental  ||| S:1884 E:1896 ||| JJ
costs  ||| S:1896 E:1902 ||| NNS
saved  ||| S:1902 E:1908 ||| VBN
and  ||| S:1908 E:1912 ||| CC
quality-adjusted  ||| S:1912 E:1929 ||| JJ
life-years  ||| S:1929 E:1940 ||| NN
( ||| S:1940 E:1941 ||| -LRB-
QALYs ||| S:1941 E:1946 ||| NNP
)  ||| S:1946 E:1948 ||| -RRB-
gained  ||| S:1948 E:1955 ||| VBD
were  ||| S:1955 E:1960 ||| VBD
small  ||| S:1960 E:1966 ||| JJ
( ||| S:1966 E:1967 ||| -LRB-
below  ||| S:1967 E:1973 ||| IN
200  ||| S:1973 E:1977 ||| CD
pounds  ||| S:1977 E:1984 ||| NNS
and  ||| S:1984 E:1988 ||| CC
0.005 ||| S:1988 E:1993 ||| NNP
,  ||| S:1993 E:1995 ||| ,
respectively ||| S:1995 E:2007 ||| RB
,  ||| S:2007 E:2009 ||| ,
per  ||| S:2009 E:2013 ||| IN
person ||| S:2013 E:2019 ||| NN
) ||| S:2019 E:2020 ||| -RRB-
.  ||| S:2020 E:2022 ||| .
Analyses  ||| S:2022 E:2031 ||| NNP
were  ||| S:2031 E:2036 ||| VBD
conducted  ||| S:2036 E:2046 ||| VBN
sampling  ||| S:2046 E:2055 ||| VBN
from  ||| S:2055 E:2060 ||| IN
the  ||| S:2060 E:2064 ||| DT
distributions  ||| S:2064 E:2078 ||| NNS
observed  ||| S:2078 E:2087 ||| VBD
from  ||| S:2087 E:2092 ||| IN
the  ||| S:2092 E:2096 ||| DT
RCTs ||| S:2096 E:2100 ||| JJ
.  ||| S:2100 E:2102 ||| .
When  ||| S:2102 E:2107 ||| WRB
all  ||| S:2107 E:2111 ||| DT
parameters  ||| S:2111 E:2122 ||| NN
were  ||| S:2122 E:2127 ||| VBD
sampled  ||| S:2127 E:2135 ||| VBN
rivaroxaban  ||| S:2135 E:2147 ||| NNS
dominated  ||| S:2147 E:2157 ||| VBD
enoxaparin  ||| S:2157 E:2168 ||| VBN
in  ||| S:2168 E:2171 ||| IN
all  ||| S:2171 E:2175 ||| DT
scenarios  ||| S:2175 E:2185 ||| NNS
except  ||| S:2185 E:2192 ||| IN
for  ||| S:2192 E:2196 ||| IN
two ||| S:2196 E:2199 ||| CD
,  ||| S:2199 E:2201 ||| ,
in  ||| S:2201 E:2204 ||| IN
which  ||| S:2204 E:2210 ||| WDT
enoxaparin  ||| S:2210 E:2221 ||| VBZ
produced  ||| S:2221 E:2230 ||| VBN
more  ||| S:2230 E:2235 ||| RBR
QALYs  ||| S:2235 E:2241 ||| JJ
than  ||| S:2241 E:2246 ||| IN
rivaroxaban  ||| S:2246 E:2258 ||| NN
and  ||| S:2258 E:2262 ||| CC
had  ||| S:2262 E:2266 ||| VBD
an  ||| S:2266 E:2269 ||| DT
incremental  ||| S:2269 E:2281 ||| JJ
cost  ||| S:2281 E:2286 ||| NN
per  ||| S:2286 E:2290 ||| IN
QALY  ||| S:2290 E:2295 ||| NNP
gained  ||| S:2295 E:2302 ||| VBD
of  ||| S:2302 E:2305 ||| IN
5000  ||| S:2305 E:2310 ||| CD
pounds  ||| S:2310 E:2317 ||| NNS
and  ||| S:2317 E:2321 ||| CC
8000  ||| S:2321 E:2326 ||| CD
pounds  ||| S:2326 E:2333 ||| NNS
respectively ||| S:2333 E:2345 ||| RB
.  ||| S:2345 E:2347 ||| .
Rivaroxaban  ||| S:2347 E:2359 ||| NNP
dominated  ||| S:2359 E:2369 ||| VBD
dabigatran  ||| S:2369 E:2380 ||| VBN
when  ||| S:2380 E:2385 ||| WRB
RECORD  ||| S:2385 E:2392 ||| NNP
1  ||| S:2392 E:2394 ||| CD
and  ||| S:2394 E:2398 ||| CC
RECORD  ||| S:2398 E:2405 ||| NNP
2 ||| S:2405 E:2406 ||| CD
,  ||| S:2406 E:2408 ||| ,
individually  ||| S:2408 E:2421 ||| RB
or  ||| S:2421 E:2424 ||| CC
pooled ||| S:2424 E:2430 ||| NN
,  ||| S:2430 E:2432 ||| ,
were  ||| S:2432 E:2437 ||| VBD
compared  ||| S:2437 E:2446 ||| VBN
with  ||| S:2446 E:2451 ||| IN
RE-NOVATE  ||| S:2451 E:2461 ||| JJ
and  ||| S:2461 E:2465 ||| CC
when  ||| S:2465 E:2470 ||| WRB
all  ||| S:2470 E:2474 ||| DT
four  ||| S:2474 E:2479 ||| CD
rivaroxaban  ||| S:2479 E:2491 ||| CD
RCTs  ||| S:2491 E:2496 ||| JJ
pooled  ||| S:2496 E:2503 ||| NN
were  ||| S:2503 E:2508 ||| VBD
compared  ||| S:2508 E:2517 ||| VBN
with  ||| S:2517 E:2522 ||| IN
all  ||| S:2522 E:2526 ||| DT
three  ||| S:2526 E:2532 ||| CD
dabigatran  ||| S:2532 E:2543 ||| JJ
RCTs ||| S:2543 E:2547 ||| NN
.  ||| S:2547 E:2549 ||| .
Dabigatran  ||| S:2549 E:2560 ||| FW
dominated  ||| S:2560 E:2570 ||| FW
rivaroxaban  ||| S:2570 E:2582 ||| FW
comparing  ||| S:2582 E:2592 ||| FW
RECORD  ||| S:2592 E:2599 ||| NNP
4  ||| S:2599 E:2601 ||| CD
with  ||| S:2601 E:2606 ||| IN
RE-MODEL  ||| S:2606 E:2615 ||| JJ
and  ||| S:2615 E:2619 ||| CC
RE-MOBILIZE ||| S:2619 E:2630 ||| JJ
,  ||| S:2630 E:2632 ||| ,
and  ||| S:2632 E:2636 ||| CC
was  ||| S:2636 E:2640 ||| VBD
more  ||| S:2640 E:2645 ||| RBR
cost-effective  ||| S:2645 E:2660 ||| JJ
than  ||| S:2660 E:2665 ||| IN
rivaroxaban  ||| S:2665 E:2677 ||| NNS
comparing  ||| S:2677 E:2687 ||| VBG
RECORD  ||| S:2687 E:2694 ||| NNP
3  ||| S:2694 E:2696 ||| CD
( ||| S:2696 E:2697 ||| -LRB-
incremental  ||| S:2697 E:2709 ||| JJ
cost  ||| S:2709 E:2714 ||| NN
per  ||| S:2714 E:2718 ||| IN
QALY  ||| S:2718 E:2723 ||| NNP
gained  ||| S:2723 E:2730 ||| VBD
of  ||| S:2730 E:2733 ||| IN
rivaroxaban  ||| S:2733 E:2745 ||| VBG
compared  ||| S:2745 E:2754 ||| VBN
with  ||| S:2754 E:2759 ||| IN
dabigatran  ||| S:2759 E:2770 ||| NN
of  ||| S:2770 E:2773 ||| IN
123,000  ||| S:2773 E:2781 ||| CD
pounds ||| S:2781 E:2787 ||| NNS
)  ||| S:2787 E:2789 ||| -RRB-
or  ||| S:2789 E:2792 ||| CC
RECORD  ||| S:2792 E:2799 ||| NNP
3  ||| S:2799 E:2801 ||| CD
and  ||| S:2801 E:2805 ||| CC
RECORD  ||| S:2805 E:2812 ||| NNP
4  ||| S:2812 E:2814 ||| CD
pooled  ||| S:2814 E:2821 ||| NNS
( ||| S:2821 E:2822 ||| -LRB-
incremental  ||| S:2822 E:2834 ||| JJ
cost  ||| S:2834 E:2839 ||| NN
per  ||| S:2839 E:2843 ||| IN
QALY  ||| S:2843 E:2848 ||| NNP
gained  ||| S:2848 E:2855 ||| VBD
of  ||| S:2855 E:2858 ||| IN
dabigatran  ||| S:2858 E:2869 ||| VBG
compared  ||| S:2869 E:2878 ||| VBN
with  ||| S:2878 E:2883 ||| IN
rivaroxaban  ||| S:2883 E:2895 ||| NN
of  ||| S:2895 E:2898 ||| IN
400  ||| S:2898 E:2902 ||| CD
pounds ||| S:2902 E:2908 ||| NNS
)  ||| S:2908 E:2910 ||| -RRB-
with  ||| S:2910 E:2915 ||| IN
RE-MODEL  ||| S:2915 E:2924 ||| JJ
and  ||| S:2924 E:2928 ||| CC
RE-MOBILIZE ||| S:2928 E:2939 ||| JJ
.  ||| S:2939 E:2941 ||| .
In  ||| S:2941 E:2944 ||| IN
conclusion ||| S:2944 E:2954 ||| NN
,  ||| S:2954 E:2956 ||| ,
the  ||| S:2956 E:2960 ||| DT
evidence  ||| S:2960 E:2969 ||| NN
indicates  ||| S:2969 E:2979 ||| VBZ
that  ||| S:2979 E:2984 ||| DT
rivaroxaban  ||| S:2984 E:2996 ||| NN
is  ||| S:2996 E:2999 ||| VBZ
not  ||| S:2999 E:3003 ||| RB
inferior  ||| S:3003 E:3012 ||| JJ
to  ||| S:3012 E:3015 ||| TO
enoxaparin  ||| S:3015 E:3026 ||| VB
in  ||| S:3026 E:3029 ||| IN
terms  ||| S:3029 E:3035 ||| NNS
of  ||| S:3035 E:3038 ||| IN
the  ||| S:3038 E:3042 ||| DT
primary  ||| S:3042 E:3050 ||| JJ
and  ||| S:3050 E:3054 ||| CC
secondary  ||| S:3054 E:3064 ||| JJ
outcomes ||| S:3064 E:3072 ||| NNS
.  ||| S:3072 E:3074 ||| .
The  ||| S:3074 E:3078 ||| DT
submission  ||| S:3078 E:3089 ||| NN
presents  ||| S:3089 E:3098 ||| VBZ
a  ||| S:3098 E:3100 ||| DT
reasonable  ||| S:3100 E:3111 ||| JJ
estimation  ||| S:3111 E:3122 ||| NN
of  ||| S:3122 E:3125 ||| IN
the  ||| S:3125 E:3129 ||| DT
cost-effectiveness  ||| S:3129 E:3148 ||| JJ
of  ||| S:3148 E:3151 ||| IN
rivaroxaban  ||| S:3151 E:3163 ||| VBG
compared  ||| S:3163 E:3172 ||| VBN
with  ||| S:3172 E:3177 ||| IN
enoxaparin  ||| S:3177 E:3188 ||| NN
and  ||| S:3188 E:3192 ||| CC
dabigatran ||| S:3192 E:3202 ||| NN
,  ||| S:3202 E:3204 ||| ,
although  ||| S:3204 E:3213 ||| IN
the  ||| S:3213 E:3217 ||| DT
uncertainty  ||| S:3217 E:3229 ||| NN
in  ||| S:3229 E:3232 ||| IN
the  ||| S:3232 E:3236 ||| DT
decision  ||| S:3236 E:3245 ||| NN
has  ||| S:3245 E:3249 ||| VBZ
been  ||| S:3249 E:3254 ||| VBN
underestimated ||| S:3254 E:3268 ||| VBN
.  ||| S:3268 E:3270 ||| .
The  ||| S:3270 E:3274 ||| DT
results  ||| S:3274 E:3282 ||| NNS
are  ||| S:3282 E:3286 ||| VBP
particularly  ||| S:3286 E:3299 ||| RB
sensitive  ||| S:3299 E:3309 ||| JJ
to  ||| S:3309 E:3312 ||| TO
any  ||| S:3312 E:3316 ||| DT
assumed  ||| S:3316 E:3324 ||| JJ
difference  ||| S:3324 E:3335 ||| NN
in  ||| S:3335 E:3338 ||| IN
the  ||| S:3338 E:3342 ||| DT
number  ||| S:3342 E:3349 ||| NN
of  ||| S:3349 E:3352 ||| IN
fatal  ||| S:3352 E:3358 ||| JJ
PEs ||| S:3358 E:3361 ||| NN
,  ||| S:3361 E:3363 ||| ,
but  ||| S:3363 E:3367 ||| CC
the  ||| S:3367 E:3371 ||| DT
ERG  ||| S:3371 E:3375 ||| NNP
does  ||| S:3375 E:3380 ||| VBZ
not  ||| S:3380 E:3384 ||| RB
believe  ||| S:3384 E:3392 ||| VBP
there  ||| S:3392 E:3398 ||| EX
is  ||| S:3398 E:3401 ||| VBZ
sufficient  ||| S:3401 E:3412 ||| JJ
evidence  ||| S:3412 E:3421 ||| NN
to  ||| S:3421 E:3424 ||| TO
support  ||| S:3424 E:3432 ||| VB
a  ||| S:3432 E:3434 ||| DT
difference  ||| S:3434 E:3445 ||| NN
between  ||| S:3445 E:3453 ||| IN
interventions ||| S:3453 E:3466 ||| NNS
.  ||| S:3466 E:3468 ||| .
The  ||| S:3468 E:3472 ||| DT
NICE  ||| S:3472 E:3477 ||| NNP
guidance  ||| S:3477 E:3486 ||| VBD
issued  ||| S:3486 E:3493 ||| VBN
as  ||| S:3493 E:3496 ||| IN
a  ||| S:3496 E:3498 ||| DT
result  ||| S:3498 E:3505 ||| NN
of  ||| S:3505 E:3508 ||| IN
the  ||| S:3508 E:3512 ||| DT
STA  ||| S:3512 E:3516 ||| NNP
states  ||| S:3516 E:3523 ||| NNS
that ||| S:3523 E:3527 ||| IN
:  ||| S:3527 E:3529 ||| :
riveroxaban ||| S:3529 E:3540 ||| CD
,  ||| S:3540 E:3542 ||| ,
within  ||| S:3542 E:3549 ||| IN
its  ||| S:3549 E:3553 ||| PRP$
marketing  ||| S:3553 E:3563 ||| NN
authorisation ||| S:3563 E:3576 ||| NN
,  ||| S:3576 E:3578 ||| ,
is  ||| S:3578 E:3581 ||| VBZ
recommended  ||| S:3581 E:3593 ||| VBN
as  ||| S:3593 E:3596 ||| IN
an  ||| S:3596 E:3599 ||| DT
option  ||| S:3599 E:3606 ||| NN
for  ||| S:3606 E:3610 ||| IN
the  ||| S:3610 E:3614 ||| DT
prevention  ||| S:3614 E:3625 ||| NN
of  ||| S:3625 E:3628 ||| IN
venous  ||| S:3628 E:3635 ||| JJ
thromboembolism  ||| S:3635 E:3651 ||| NN
in  ||| S:3651 E:3654 ||| IN
adults  ||| S:3654 E:3661 ||| NNS
having  ||| S:3661 E:3668 ||| VBG
elective  ||| S:3668 E:3677 ||| JJ
THR  ||| S:3677 E:3681 ||| NNP
or  ||| S:3681 E:3684 ||| CC
elective  ||| S:3684 E:3693 ||| JJ
TKB ||| S:3693 E:3696 ||| NNP
.  ||| S:3696 E:3698 ||| .
